Knothe H, Dette G A
Infection. 1983;11 Suppl 1:S12-5. doi: 10.1007/BF01641098.
An increasing number of new cephalosporins continue to become available in the clinic so that the clinician requires something akin to Ariadne's thread to work through the labyrinth of confusing names and product claims. The parenteral cephalosporins may be grouped on the basis of structure, antimicrobial activity and metabolic stability as follows: 1. cephacetrile, cephalothin, cefapirin; 2. cefotaxime; 3. cephaloridine, cefazedone, cefazolin, cefotiam; 4. cefamandole, cefoperazone, cefsulodin, cefuroxime, cefoxitin, ceftazidime, ceftizoxime, ceftriaxone, lamoxactam. Groups 2 and 4 contain the most interesting compounds in terms of their biological activity and therapeutic significance. Even carbenicillin-resistant strains of Pseudomonas aeruginosa are inhibited by one of the recent broad-spectrum cephalosporins. In the clinic, minor differences between the highly active cephalosporins are not likely to be of therapeutic significance.
临床上越来越多的新型头孢菌素不断问世,这使得临床医生需要类似阿里阿德涅之线的东西,来理清令人困惑的名称和产品宣称的迷宫。胃肠外使用的头孢菌素可根据结构、抗菌活性和代谢稳定性进行如下分类:1. 头孢乙腈、头孢噻吩、头孢匹林;2. 头孢噻肟;3. 头孢噻啶、头孢替唑、头孢唑林、头孢替安;4. 头孢孟多、头孢哌酮、头孢磺啶、头孢呋辛、头孢西丁、头孢他啶、头孢唑肟、头孢曲松、拉氧头孢。就其生物活性和治疗意义而言,第2组和第4组包含了最有趣的化合物。甚至对羧苄西林耐药的铜绿假单胞菌菌株也能被一种最新的广谱头孢菌素所抑制。在临床上,高活性头孢菌素之间的微小差异不太可能具有治疗意义。